https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2026-01-06 08:30:212026-01-06 08:21:14LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2025-08-05 15:00:572025-08-05 15:00:57Our Co-Founder and CSO Caroline Benn spoke with Eva Haas of Optimum Strategic Communications for an episode of the Optimum Perspectives podcast.
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2025-02-18 08:30:032025-02-18 08:30:03LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2025-01-29 11:23:572025-02-12 11:29:41Cambridge, UK based LoQus23 Therapeutics will use a small molecule allosteric inhibitor of MutSβ to treat Huntington’s
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2024-10-02 08:30:022024-10-02 11:27:05LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Amanda Davishttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngAmanda Davis2022-07-27 14:11:302022-07-27 14:11:44LoQus23 and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Amanda Davishttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngAmanda Davis2022-05-11 12:35:322022-05-12 09:30:42LoQus23 Therapeutics Ltd. of Cambridge, UK co-funds new research project on neurological diseases
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Amanda Davishttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngAmanda Davis2022-01-24 19:00:452022-01-25 11:27:43LoQus23 Therapeutics appoints Dr Melanie Ivarsson, OBE, as Non-Executive Director
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2021-11-23 09:00:402021-11-29 21:48:33LoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2021-07-27 10:09:282021-11-18 10:23:32LoQus23 researchers awarded grant to understand if repeat instability is therapeutically relevant in Friedriech’s ataxia
LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease
Our Co-Founder and CSO Caroline Benn spoke with Eva Haas of Optimum Strategic Communications for an episode of the Optimum Perspectives podcast.
LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors
Cambridge, UK based LoQus23 Therapeutics will use a small molecule allosteric inhibitor of MutSβ to treat Huntington’s
LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease
LoQus23 and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
LoQus23 Therapeutics Ltd. of Cambridge, UK co-funds new research project on neurological diseases
LoQus23 Therapeutics appoints Dr Melanie Ivarsson, OBE, as Non-Executive Director
LoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund
LoQus23 researchers awarded grant to understand if repeat instability is therapeutically relevant in Friedriech’s ataxia